Differentiation of brain tumor recurrence from post-radiotherapy necrosis with 11C-methionine PET: Visual assessment versus quantitative assessment

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Minamimoto, Ryogo ^a   Saginoya, Toshiyuki ^b   Kondo, Chisato ^c   Tomura, Noriaki ^b   Ito, Kimiteru ^d   Matsuo, Yuka ^c   Matsunaga, Shigeo ^e   Shuto, Takashi ^e   Akabane, Atsuya ^f   Miyata, Yoko ^g   Sakai, Shuji ^c   Kubota, Kazuo ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b Southern Tohoku General Hospital   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^e YOKOHAMA ROSAI HOSPITAL   (Japan)

^f Nippon Telegraph and Telephone Corporation Medical Center Tokyo   (Japan)

^g National Center for Global Health and Medicine   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

METHIONINE C 11; CARBON; METHIONINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BRAIN METASTASIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CEREBELLUM CORTEX; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FRONTAL LOBE; GLIOMA; HUMAN; IMAGE PROCESSING; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OBSERVER VARIATION; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; RADIATION DOSE DISTRIBUTION; RADIATION NECROSIS; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; BRAIN; BRAIN NEOPLASMS; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; METABOLISM; MIDDLE AGED; NECROSIS; NEUROIMAGING; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BRAIN; BRAIN NEOPLASMS; CARBON RADIOISOTOPES; DIAGNOSIS, DIFFERENTIAL; FEMALE; GLIOMA; HUMANS; MALE; METHIONINE; MIDDLE AGED; NECROSIS; NEOPLASM RECURRENCE, LOCAL; NEUROIMAGING; OBSERVER VARIATION; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES;

EID: 84940706345     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0132515     Document Type: Article

References (27)

1. Ishiwata K, Kubota K, Murakami M, Kubota R, Sasaki T, Ishii S, et al. (1993) Re-evaluation of amino acid PET studies: can the protein synthesis rates in brain and tumor tissues be measured in vivo? J Nucl Med 34 (11):1936-43. PMID: 8229238
2. 11C-Methionine PET for differential diagnosis of low-grade gliomas. Neurology 50 (5):1316-22. PMID: 9595980
3. 11Cmethionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med 45 (8): 1293-8. PMID: 15299051
4. Hygino da Cruz LC Jr, Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG (2011). Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 32(11):1978-85. doi: 10.3174/ajnr.A2397 PMID: 21393407
5. 18F-FDG PET. Eur J Nucl Med Mol Imaging 29 (2):176-82. PMID: 11926379
6. 11C]- l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging 30 (6):868-73. PMID: 12692687
7. 11C-Methionine PET for Differentiation of Recurrent Brain Tumors from Radiation Necrosis After Radiotherapy. J Nucl Med 49 (5):694-9. doi: 10.2967/jnumed.107.048082 PMID: 18413375
8. Tsuyuguchi N, Sunada I, Iwai Y, Yamanaka K, Tanaka K, Takami T, et al. (2003) Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radio-surgery: is a differential diagnosis possible? J Neurosurg 98 (5): 1056-64. PMID: 12744366
9. Tripathi M, Sharma R, Varshney R, Jaimini A, Jain J, Souza MM, et al. (2012) Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors. Clin Nucl Med 37 (2): 158-63. doi: 10.1097/RLU.0b013e318238f51a PMID: 22228339
10. Yamane T, Sakamoto S, Senda M (2010) Clinical impact of (11)C methionine PET on expected management of patients with brain neoplasm. Eur J Nucl Med Mol Imaging 37 (4): 685-90. doi: 10.1007/s00259-009-1302-y PMID: 19915838
11. 11C] methionine (MET)-PET in patients with brain gliomas and metastases. Int J Radiat Oncol Biol Phys 81 (4):1049-58. doi: 10.1016/j.ijrobp.2010.07.002 PMID: 21570201
12. Galldiks N, Stoffels G, Filss CP, Piroth MD, Sabel M, Ruge MI, et al (2012). Role of O-(2-(18)F-fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis. J Nucl Med 53(9):1367-74. doi: 10.2967/jnumed.112.103325 PMID: 22872742
13. Karunanithi S, Sharma P, Kumar A, Khangembam BC, Bandopadhyaya GP, Kumar R, et al (2013). 18F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging 40(7):1025-35. doi: 10.1007/s00259-013-2384-0 PMID: 23525498
14. 11C-methionine PET in imaging brain tumors and metastases. Eur J Nucl Med Mol Imaging 40 (4): 615-35. doi: 10.1007/s00259-012-2295-5 PMID: 23232505
15. rd ed. Chapter 18. New York: Wiely, 598-626.
16. DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44 (3):837-45. PMID: 3203132
17. 18F-FDG PET, 11Cmethionine PET and perfusion MRI. Clin Neurol Neurosurg 112 (9):758-65. doi: 10.1016/j.clineuro.2010.06.005 PMID: 20619531
18. Tsuyuguchi N, Takami T, Sunada I, Iwai Y, Yamanaka K, Tanaka K, et al. (2004) Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery-in malignant glioma. Ann Nucl Med 18 (4):291-6. PMID: 15359921
19. Okamoto S, Shiga T, Hattori N, Kubo N, Takei T, Katoh N, et al. (2011) Semiquantitative analysis of C-11 methionine PET may distinguish brain tumor recurrence from radiation necrosis even in small lesions. Ann Nucl Med 25 (3): 213-20. doi: 10.1007/s12149-010-0450-2 PMID: 21188660
20. 11C-methionine PET with reference to a normal methionine uptake map. J Nucl Med 48 (12):1971-80. PMID: 18006617
21. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomized trial. Lancet 2363 (9422): 1665-72.
22. Laperriere N, Zuraw L, Cairncross G (2002) Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site Group: Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 64 (3): 259-73. PMID: 12242114
23. Pöpperl G, Götz C, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K (2004) Value of O-(2-[18F]fluoroethyl)-L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 31 (11):1464-70. PMID: 15248032
24. Torcuator R, Zuniga R, Mohan YS, Rock J, Doyle T, Anderson J, et al. (2009) Initial experience with Bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol 94 (1): 63-8. doi: 10.1007/s11060-009-9801-z PMID: 19189055
25. Matuschek C, Bölke E, Nawatny J, Hoffmann TK, Peiper M, Orth K, et al. (2011) Bevacizumab as a treatment option for radiation-induced cerebral necrosis. Strahlenther Onkol 187 (2):135-9. doi: 10.1007/s00066-010-2184-4 PMID: 21336713
26. Nonoguchi N, Miyatake S, Fukumoto M, Furuse M, Hiramatsu R, Kawabata S, et al. (2011) The distribution of vascular endothelial growth factor-producing cells in clinical radiation necrosis of the brain:pathological consideration of their potential roles. J Neurooncol 105 (2):423-31. doi: 10.1007/s11060-011-0610-9 PMID: 21688077
27. Furuse M, Nonoguchi N, Kawabata S, Yoritsune E, Takahashi M, Inomata T, et al. (2013) Bevacizumab treatment for symptomatic radiation necrosis diagnosed by amino acid PET. Jpn J Clin Oncol 43 (3):337-41. doi: 10.1093/jjco/hys231 PMID: 23303838